News

Esbriet (pirfenidone) has an acceptable level of tolerability in patients with systemic sclerosis (SSc) associated with interstitial lung disease (ILD), and may be tested for efficacy in future clinical trials in these patients, according to the results of a randomized Phase 2 study, the LOTUSS trial. The study, “An…

A study showed the effectiveness of hydrogen sulfide in a mouse model of scleroderma, and researchers in China suggest that the compound should be explored as a potential treatment for patients. The study, “The protective effect of hydrogen sulfide on systemic sclerosis associated skin and lung fibrosis in mice model,” published…

Scleroderma patients with pulmonary arterial hypertension (PAH) benefit equally well from treatment with Adempas (riociguat) as PAH patients with other types of connective tissue disease (PAH-CTD), according to research from the University of Paris-Saclay in France. The study, “Riociguat for the treatment of pulmonary arterial hypertension…

This week, Scleroderma News reported on the recent study, “Watermelon stomach and colon in a patient with diffuse cutaneous systemic sclerosis,” published in the journal Modern Rheumatology. The news article informs us that: ‘GI complications, such as hemorrhages, low esophageal motility, and bacterial overgrowth, are common in…

A direct comparison of Cytoxan (Cyclophosphamide) and Cellcept (mycophenolate mofetil) showed that the drugs are equally effective in stabilizing, and even improving, lung function in scleroderma patients with lung fibrosis. Since Cytoxan might be more toxic when used for extended periods, the study, “Cyclophosphamide versus mycophenolate mofetil…

Systemic sclerosis may lead to the appearance of gastrointestinal (GI) lesions that resemble the stripes of a watermelon, which explains the expression “watermelon stomach.” Although it is often restricted to the stomach, researchers presented, for what is believed to be the first time, a case of watermelon stomach and colon.

A case study, describing the successful treatment of a scleroderma patient with repeated therapeutic plasma exchange (TPE) for more than 22 years, presents an alternative theory about the beneficial effects of the treatment and the disease itself. The study “Successful long-term (22 Year) treatment of limited scleroderma…

A new clinical trial assessing neuropsychiatric complications in patients with systemic sclerosis — like depression and cognitive problems — is starting in France and currently recruiting patients. Until recently, systemic sclerosis (often also referred to as scleroderma)  — a connective tissue disorder — was thought to spare the central nervous system…

  Expert specialist centers are essential requirements in ensuring for the best care and treatment of scleroderma patients, as well as for the rare disease patient in general. The experience, knowledge, and understanding of a medical specialist not only offers increased comfort to the patient, but the greatest likelihood of an early diagnosis, optimal care,…

The National Institute of Allergy and Infectious Diseases is recruiting patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) to assess if Rituxan (rituximab) immunotherapy is effective against disease progression. The randomized Phase 2 study, titled “Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH),” is enrolling patients…